Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

May 7, 2019

Study Completion Date

May 7, 2019

Conditions
Chronic Hemodialysis (ESRD)
Interventions
DRUG

Hydralazine/Isorsorbide Dinitrate

"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."

DRUG

Placebo

Placebo titration will mimic titration of active study arm

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT02228408 - Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD | Biotech Hunter | Biotech Hunter